Investors’ outlook regarding the stock price performance over the year has been a mixed bag, with a range of optimism to pessimism depending on their perspective. The index has shown a price gain of 35.63% this year. Over the last six months, there has been a weaker performance of 100.00%. The price of SMMT leaped by -30.18% during the last 30 days period. For the last 5-days stocks have slided -5.60%.
Summit Therapeutics Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $5.22 on 03/05/24 and the lowest value was $1.30 on 04/28/23.
52-week price history of SMMT Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Summit Therapeutics Inc’s current trading price is -32.18% away from its 52-week high, while its distance from the 52-week low is 172.31%. The stock’s price range during this period has varied between$1.30 and $5.22. The Summit Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 2.33 million for the day, a figure considerably lower than their average daily volume of 2.35 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Summit Therapeutics Inc (SMMT) has experienced a quarterly rise of 31.11% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 2.48B and boasts a workforce of 105 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 3.36, with a change in price of +1.71. Similarly, Summit Therapeutics Inc recorded 1,934,615 in trading volume during the last 100 days, posting a change of +93.97%.
SMMT’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for SMMT stands at 1.37. Similarly, the long-term debt-to-equity ratio is also 1.33.
SMMT Stock Stochastic Average
Summit Therapeutics Inc’s raw stochastic average for the past 50 days is presently 14.72%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 16.38%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 27.96% and 33.46%, respectively.
